BIOMEVA and Boehringer Ingelheim strengthen their biomanufacturing services in a production alliance
BIOMEVA GmbH and Boehringer Ingelheim announced that both companies have entered into a production alliance agreement. With this collaboration BIOMEVA GmbH may have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing technology platform including formulation development for microbial derived products.
The collaboration with Boehringer Ingelheim complements BIOMEVA GmbH´s current manufacturing capacities with large scale manufacturing capabilities allowing speed and flexibility, and securing high value for the customers.
Already one E.coli project regarding an antibody fragment has been transferred smoothly from Boehringer Ingelheim Austria GmbH to BIOMEVA GmbH. The process has been implemented successfully in a very short time and first GMP runs have been performed already five weeks after the first technology transfer meeting. Seven weeks later GMP material has been released for clinical trials.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology - Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
K-State researcher, collaborators study virulence of pandemic H1N1 virus
XOMA Licenses BCE Technology for Recombinant Protein Production to Wyeth
Colorado BioScience Association - Denver, USA

Sinonasal cancer: AI facilitates breakthrough in diagnostics - Researchers have developed a method for classifying difficult-to-diagnose nasal cavity tumors
American_Society_of_Cytopathology

Starting up with highly promising immunotherapies - Fighting cancer with specially equipped T cells

Alzheimer’s disease: Protective immune response in the brain?

Nanoparticles to target, kill endometrial cancer
